Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
$0.08
+2.0%		$0.08
$0.04
▼
$0.12
$13.87M-0.7720,144 shs10,500 shs
RYTHM, Inc. stock logo
RYM
RYTHM
$22.08
-11.6%		$24.03
$14.00
▼
$53.65
$54.46M9.4712,190 shs9,859 shs
Scilex Holding Company stock logo
SCLX
Scilex
$6.94
+6.4%		$7.66
$4.20
▼
$34.27
$55.36M1.6784,058 shs65,286 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$5.20
+0.8%		$4.36
$3.53
▼
$10.48
$51.24M1.09245,976 shs67,384 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
+2.01%+1.75%+3.69%-2.05%+56.84%
RYTHM, Inc. stock logo
RYM
RYTHM
-11.64%+20.66%-7.88%-15.69%+2,207,999,900.00%
Scilex Holding Company stock logo
SCLX
Scilex
+6.44%+5.15%-30.11%-11.25%-53.45%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+0.78%+39.41%+12.80%-29.02%-11.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
$0.08
+2.0%		$0.08
$0.04
▼
$0.12
$13.87M-0.7720,144 shs10,500 shs
RYTHM, Inc. stock logo
RYM
RYTHM
$22.08
-11.6%		$24.03
$14.00
▼
$53.65
$54.46M9.4712,190 shs9,859 shs
Scilex Holding Company stock logo
SCLX
Scilex
$6.94
+6.4%		$7.66
$4.20
▼
$34.27
$55.36M1.6784,058 shs65,286 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$5.20
+0.8%		$4.36
$3.53
▼
$10.48
$51.24M1.09245,976 shs67,384 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
+2.01%+1.75%+3.69%-2.05%+56.84%
RYTHM, Inc. stock logo
RYM
RYTHM
-11.64%+20.66%-7.88%-15.69%+2,207,999,900.00%
Scilex Holding Company stock logo
SCLX
Scilex
+6.44%+5.15%-30.11%-11.25%-53.45%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+0.78%+39.41%+12.80%-29.02%-11.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
0.00
N/AN/AN/A
RYTHM, Inc. stock logo
RYM
RYTHM
1.00
SellN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
1.00
SellN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
2.33
Hold$24.00361.54% Upside

Current Analyst Ratings Breakdown

Latest INTI, RYM, SCLX, and SCYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Brookline Capital Markets logo
Brookline Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/24/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/10/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/26/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/16/2026
Scilex Holding Company stock logo
SCLX
Scilex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/12/2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/18/2026
RYTHM, Inc. stock logo
RYM
RYTHM
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/AN/AN/AN/A($0.01) per shareN/A
RYTHM, Inc. stock logo
RYM
RYTHM
$17.28M2.79N/AN/A$17.94 per share1.23
Scilex Holding Company stock logo
SCLX
Scilex
$33.86M1.74N/AN/A($24.94) per share-0.28
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$20.34M2.54N/AN/A$9.07 per share0.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
-$3.30M-$0.01N/AN/AN/AN/A-1,693.49%-122.07%N/A
RYTHM, Inc. stock logo
RYM
RYTHM
-$33.26M-$10.53N/AN/AN/A-6.20%-12.57%-2.60%N/A
Scilex Holding Company stock logo
SCLX
Scilex
-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$8.61M-$3.84N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)

Latest INTI, RYM, SCLX, and SCYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026Q2 2026
Scilex Holding Company stock logo
SCLX
Scilex
-$0.1813N/AN/AN/A$16.00 millionN/A
8/12/2026Q2 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.5067N/AN/AN/A$0.08 millionN/A
8/4/2026Q2 2026
RYTHM, Inc. stock logo
RYM
RYTHM
N/A$0.09N/A$0.09N/A$23.02 million
5/20/2026Q1 2026
Scilex Holding Company stock logo
SCLX
Scilex
-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million
5/11/2026Q1 2026
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.10-$0.42-$0.32-$3.36$0.08 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/AN/AN/AN/AN/A
RYTHM, Inc. stock logo
RYM
RYTHM
N/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/A
3.60
3.60
RYTHM, Inc. stock logo
RYM
RYTHM
N/A
0.59
0.48
Scilex Holding Company stock logo
SCLX
Scilex
N/A
0.08
0.07
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
3.94
3.94

Institutional Ownership

CompanyInstitutional Ownership
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/A
RYTHM, Inc. stock logo
RYM
RYTHM
5.98%
Scilex Holding Company stock logo
SCLX
Scilex
69.67%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
4.60%
RYTHM, Inc. stock logo
RYM
RYTHM
3.48%
Scilex Holding Company stock logo
SCLX
Scilex
4.50%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
1173.79 million165.80 millionNot Optionable
RYTHM, Inc. stock logo
RYM
RYTHM
1402.18 million2.10 millionN/A
Scilex Holding Company stock logo
SCLX
Scilex
808.49 million8.11 millionNo Data
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
609.93 million9.52 millionOptionable

Recent News About These Companies

SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday
August 5 at 9:10 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/scynexis-scyx-projected-to-post-quarterly-earnings-on-wednesday-2026-08-05/
SCYNEXIS (NASDAQ:SCYX) Shares Cross Below Two Hundred Day Moving Average - What's Next?
August 4 at 3:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30940137
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319628/0/en/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd.html
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
June 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scynexis-shareholders-approve-governance-and-equity-plan-changes?utm_source=marketbeat.com&utm_medium=referral
SCYNEXIS Inc.
June 24, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/SCYX/financials
SCYNEXIS Announces One-for-Eight Reverse Stock Split
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300360/0/en/scynexis-announces-one-for-eight-reverse-stock-split.html
SCYNEXIS (SCYX) price target increased by 20.73% to 4.28
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/scynexis-scyx-price-target-increased-by-2073-to-428/ar-AA23cbkM
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/11/3292371/0/en/scynexis-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289542/0/en/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
SCYNEXIS Raises $40 Million in Strategic Private Placement
April 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCYX/pressreleases/1093176/scynexis-raises-40-million-in-strategic-private-placement/
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
March 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4887596-scynexis-inc-scyx-discusses-transformative-asset-acquisition-and-strategic-shift-toward-adpkd
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...
March 31, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-1035979917
Why did SCYX stock jump 10% in pre-market today?
March 31, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/why-did-scyx-stock-jump-10-in-pre-market-today/ar-AA1ZP1Uy
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
March 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260331538575/en/poxel-announces-the-sale-of-pxl770-to-scynexis-for-a-total-amount-of-up-to-196-million/
SCYNEXIS Announces $40.0 Million Private Placement
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265281/0/en/scynexis-announces-40-0-million-private-placement.html
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265277/0/en/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpk.html
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
March 12, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/scynexis-inc-scyx-announces-first-participants-dosed-in-phase-1-trial-of-scy-247-antifungal-therapy-1714281/
Scynexis: Q4 Earnings Snapshot
March 4, 2026  |  wiltonbulletin.comW
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
March 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/04/3249748/0/en/scynexis-reports-full-year-2025-financial-results-and-provides-corporate-update.html
SCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA Designations
February 26, 2026  |  quiverquant.comQ
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
February 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/26/3245564/0/en/scynexis-announces-first-participants-dosed-in-a-phase-1-single-ascending-dose-and-multiple-ascending-dose-trial-of-intravenous-scy-247.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center server aisle with a digital globe and shield graphic symbolizing cybersecurity, alongside monitors displaying network data.
Cybersecurity Stocks Are Holding Up as the AI Trade Starts to Crack
By Ryan Hasson | July 20, 2026
Velo3D logo overlaid on a 3D-printed lattice sculpture inside an industrial metal 3D printer.
Velo3D Forges a New Reality After Its Sharp Stock Sell-Off
By Jeffrey Neal Johnson | July 22, 2026
Illustration of a glowing Meta symbol connected by cables atop a server circuit board, symbolizing data or AI infrastructure.
Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
By Leo Miller | August 5, 2026
Amprius Technologies logo displayed over a battery manufacturing facility with lithium-ion battery packs on assembly equipment.
Amprius Technologies Validates Growth Trajectory With Q2 Earnings—What Comes Next?
By Thomas Hughes | August 6, 2026
Apple logo on a MacBook underscores new low-cost device launches aimed at boosting market share.
Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test
By Sam Quirke | July 27, 2026
Inhibitor Therapeutics stock logo

Inhibitor Therapeutics OTCMKTS:INTI

$0.08 +0.00 (+2.01%)
As of 08/6/2026 12:42 PM Eastern

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

RYTHM stock logo

RYTHM NASDAQ:RYM

$22.08 -2.91 (-11.64%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$21.98 -0.09 (-0.43%)
As of 08/6/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

Scilex stock logo

Scilex NASDAQ:SCLX

$6.94 +0.42 (+6.44%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$6.82 -0.12 (-1.66%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$5.20 +0.04 (+0.78%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$5.32 +0.12 (+2.31%)
As of 08/6/2026 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas